Intracavitary doxorubicin hydrochloride treatment for carcinoma in situ of the urinary bladder. A comparative study of two therapy regimens.
In two subsequent, non-randomized groups of 9 patients with carcinoma in situ doxorubicin hydrochloride was applied intravesically. The dosage used was 40 and 80 mg. Tumour remission was obtained in 6 patients per group. The tumour grade might be of prognostic value. Cold cup random biopsies are warranted in the follow-up.
D000328:Adult; D000368:Aged; D002278:Carcinoma in Situ / Q000188:drug therapy* / Q000473:pathology; D004317:Doxorubicin / Q000008:administration & dosage* / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000473:pathology
D004317:Doxorubicin